Tumor antigens — Drug Target
All drugs that target Tumor antigens — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Personalized neoantigen vaccine
Phase 1 pipeline (1)
- APVAC1 vaccine plus Poly-ICLC and GM-CSF · Immatics Biotechnologies GmbH · Personalized neoantigen vaccine · Oncology
APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.